249 related articles for article (PubMed ID: 36972292)
21.
Shutinoski B; Hakimi M; Harmsen IE; Lunn M; Rocha J; Lengacher N; Zhou YY; Khan J; Nguyen A; Hake-Volling Q; El-Kodsi D; Li J; Alikashani A; Beauchamp C; Majithia J; Coombs K; Shimshek D; Marcogliese PC; Park DS; Rioux JD; Philpott DJ; Woulfe JM; Hayley S; Sad S; Tomlinson JJ; Brown EG; Schlossmacher MG
Sci Transl Med; 2019 Sep; 11(511):. PubMed ID: 31554740
[TBL] [Abstract][Full Text] [Related]
22. Leprosy susceptibility: genetic variations regulate innate and adaptive immunity, and disease outcome.
Cardoso CC; Pereira AC; de Sales Marques C; Moraes MO
Future Microbiol; 2011 May; 6(5):533-49. PubMed ID: 21585261
[TBL] [Abstract][Full Text] [Related]
23. Common polymorphisms in the NOD2 gene region are associated with leprosy and its reactive states.
Berrington WR; Macdonald M; Khadge S; Sapkota BR; Janer M; Hagge DA; Kaplan G; Hawn TR
J Infect Dis; 2010 May; 201(9):1422-35. PubMed ID: 20350193
[TBL] [Abstract][Full Text] [Related]
24. NOD2c.3019-3020insC AND c.2104C>T GENE VARIANTS AMONG PATIENTS FROM WESTERN UKRAINE WITH CROHN'S DISEASE AND COLORECTAL CANCER.
Lozynska L; Pinyazhko R; Lozynska M; Plawski A; Makukh H; Lukavetskyy O; Grzegotsky M; Pinyazhko O
Exp Oncol; 2022 May; 44(1):52-59. PubMed ID: 35548966
[TBL] [Abstract][Full Text] [Related]
25. The NOD2 p.Leu1007fsX1008 mutation (rs2066847) is a stronger predictor of the clinical course of Crohn's disease than the FOXO3A intron variant rs12212067.
Schnitzler F; Friedrich M; Wolf C; Angelberger M; Diegelmann J; Olszak T; Beigel F; Tillack C; Stallhofer J; Göke B; Glas J; Lohse P; Brand S
PLoS One; 2014; 9(11):e108503. PubMed ID: 25365249
[TBL] [Abstract][Full Text] [Related]
26. Genomewide association study of leprosy.
Wong SH; Hill AV; Vannberg FO;
N Engl J Med; 2010 Apr; 362(15):1446-7; author reply 1447-8. PubMed ID: 20393182
[No Abstract] [Full Text] [Related]
27. The prognostic power of the NOD2 genotype for complicated Crohn's disease: a meta-analysis.
Adler J; Rangwalla SC; Dwamena BA; Higgins PD
Am J Gastroenterol; 2011 Apr; 106(4):699-712. PubMed ID: 21343918
[TBL] [Abstract][Full Text] [Related]
28. [NOD2 gene mutation in Moroccan patients with Crohn's disease: prevalence, genotypic study and correlation of NOD2 gene mutation with the phenotype of Crohn's disease].
Tamzaourte M; Errabih I; Krami H; Maha F; Maria L; Benzzoubeir N; Ouazzani L; Sefiani A; Ouazzani H
Pan Afr Med J; 2017; 27():116. PubMed ID: 28819537
[TBL] [Abstract][Full Text] [Related]
29. Variants of NOD1 and NOD2 genes display opposite associations with familial risk of Crohn's disease and anti-saccharomyces cerevisiae antibody levels.
Vasseur F; Sendid B; Jouault T; Standaert-Vitse A; Dubuquoy L; Francois N; Gower-Rousseau C; Desreumaux P; Broly F; Vermeire S; Colombel JF; Poulain D
Inflamm Bowel Dis; 2012 Mar; 18(3):430-8. PubMed ID: 21739538
[TBL] [Abstract][Full Text] [Related]
30. Pathogenic LRRK2 variants are gain-of-function mutations that enhance LRRK2-mediated repression of β-catenin signaling.
Berwick DC; Javaheri B; Wetzel A; Hopkinson M; Nixon-Abell J; Grannò S; Pitsillides AA; Harvey K
Mol Neurodegener; 2017 Jan; 12(1):9. PubMed ID: 28103901
[TBL] [Abstract][Full Text] [Related]
31. Function and dysfunction of leucine-rich repeat kinase 2 (LRRK2): Parkinson's disease and beyond.
Bae JR; Lee BD
BMB Rep; 2015 May; 48(5):243-8. PubMed ID: 25703537
[TBL] [Abstract][Full Text] [Related]
32. [NOD2/CARD15 mutations and genotype-phenotype correlations in patients with Crohn's disease. Hungarian multicenter study].
Lakatos L; Lakatos PL; Willheim-Polli C; Reinisch W; Ferenci P; Tulassay Z; Molnár T; Kovács A; Papp J; Szalay F;
Orv Hetil; 2004 Jul; 145(27):1403-11. PubMed ID: 15320482
[TBL] [Abstract][Full Text] [Related]
33. Parkinson's disease-linked LRRK2 is expressed in circulating and tissue immune cells and upregulated following recognition of microbial structures.
Hakimi M; Selvanantham T; Swinton E; Padmore RF; Tong Y; Kabbach G; Venderova K; Girardin SE; Bulman DE; Scherzer CR; LaVoie MJ; Gris D; Park DS; Angel JB; Shen J; Philpott DJ; Schlossmacher MG
J Neural Transm (Vienna); 2011 May; 118(5):795-808. PubMed ID: 21552986
[TBL] [Abstract][Full Text] [Related]
34. The intermediate filament protein, vimentin, is a regulator of NOD2 activity.
Stevens C; Henderson P; Nimmo ER; Soares DC; Dogan B; Simpson KW; Barrett JC; ; Wilson DC; Satsangi J
Gut; 2013 May; 62(5):695-707. PubMed ID: 22684479
[TBL] [Abstract][Full Text] [Related]
35. Association of LRRK2 exonic variants with susceptibility to Parkinson's disease: a case-control study.
Ross OA; Soto-Ortolaza AI; Heckman MG; Aasly JO; Abahuni N; Annesi G; Bacon JA; Bardien S; Bozi M; Brice A; Brighina L; Van Broeckhoven C; Carr J; Chartier-Harlin MC; Dardiotis E; Dickson DW; Diehl NN; Elbaz A; Ferrarese C; Ferraris A; Fiske B; Gibson JM; Gibson R; Hadjigeorgiou GM; Hattori N; Ioannidis JP; Jasinska-Myga B; Jeon BS; Kim YJ; Klein C; Kruger R; Kyratzi E; Lesage S; Lin CH; Lynch T; Maraganore DM; Mellick GD; Mutez E; Nilsson C; Opala G; Park SS; Puschmann A; Quattrone A; Sharma M; Silburn PA; Sohn YH; Stefanis L; Tadic V; Theuns J; Tomiyama H; Uitti RJ; Valente EM; van de Loo S; Vassilatis DK; Vilariño-Güell C; White LR; Wirdefeldt K; Wszolek ZK; Wu RM; Farrer MJ;
Lancet Neurol; 2011 Oct; 10(10):898-908. PubMed ID: 21885347
[TBL] [Abstract][Full Text] [Related]
36. Pleiotropic effects for Parkin and LRRK2 in leprosy type-1 reactions and Parkinson's disease.
Fava VM; Xu YZ; Lettre G; Van Thuc N; Orlova M; Thai VH; Tao S; Croteau N; Eldeeb MA; MacDougall EJ; Cambri G; Lahiri R; Adams L; Fon EA; Trempe JF; Cobat A; Alcaïs A; Abel L; Schurr E
Proc Natl Acad Sci U S A; 2019 Jul; 116(31):15616-15624. PubMed ID: 31308240
[TBL] [Abstract][Full Text] [Related]
37. Leucine-Rich Repeat Kinase (LRRK2) Genetics and Parkinson's Disease.
Monfrini E; Di Fonzo A
Adv Neurobiol; 2017; 14():3-30. PubMed ID: 28353276
[TBL] [Abstract][Full Text] [Related]
38. Impaired antibacterial autophagy links granulomatous intestinal inflammation in Niemann-Pick disease type C1 and XIAP deficiency with NOD2 variants in Crohn's disease.
Schwerd T; Pandey S; Yang HT; Bagola K; Jameson E; Jung J; Lachmann RH; Shah N; Patel SY; Booth C; Runz H; Düker G; Bettels R; Rohrbach M; Kugathasan S; Chapel H; Keshav S; Elkadri A; Platt N; Muise AM; Koletzko S; Xavier RJ; Marquardt T; Powrie F; Wraith JE; Gyrd-Hansen M; Platt FM; Uhlig HH
Gut; 2017 Jun; 66(6):1060-1073. PubMed ID: 26953272
[TBL] [Abstract][Full Text] [Related]
39. Crohn's disease-associated NOD2 variants share a signaling defect in response to lipopolysaccharide and peptidoglycan.
Bonen DK; Ogura Y; Nicolae DL; Inohara N; Saab L; Tanabe T; Chen FF; Foster SJ; Duerr RH; Brant SR; Cho JH; Nuñez G
Gastroenterology; 2003 Jan; 124(1):140-6. PubMed ID: 12512038
[TBL] [Abstract][Full Text] [Related]
40. LRRK2 and the Immune System.
Dzamko NL
Adv Neurobiol; 2017; 14():123-143. PubMed ID: 28353282
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
